Stock Price Prediction

JPMorgan lowered the firm's price target on Owens & Minor to $10 from $14. The firm keeps an Underweight rating on the shares due to a "variety of moving parts" and continued uncertainty and improvement initiatives underway, the analyst tells investors in a research note. The firm notes continued challenges in demand and pricing for personal protective equipment as well as uncertainty around the ability to continue to offset headwinds on the cost side, and says that while Apria continues to drive performance in the Patient Direct business, broader reimbursement risk remains over the long-term and JPMorgan sees Rotech's acquisition as a swing factor.